InflaRx (Nasdaq: IFRX) is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. Complement C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. InflaRx was founded in 2007 and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI and New York, NY, USA. Source
No articles found.
Semler Scientific, Inc. is an emerging medical risk-assessment company whose diagn...
Semler Scientific, Inc. is an emerging medical ...
At Delee, we aim to radically change the way cancer is detected, monitored and tre...
At Delee, we aim to radically change the way ca...
Lab Sensor Solutionsâ mission is to improve lives through the use of real-time s...
Lab Sensor Solutionsâ mission is to improve l...
Intrommune Therapeutics is a New York City-based biopharmaceutical company develop...
Intrommune Therapeutics is a New York City-base...
Acorda Therapeutics is a biotechnology company focused on developing therapies tha...
Acorda Therapeutics is a biotechnology company ...
Bayer is a global enterprise with core competencies in the life science fields of ...
Bayer is a global enterprise with core competen...
Morphic Therapeutic is leading the development of a new generation of oral integri...
Morphic Therapeutic is leading the development ...
Equillium is a biotechnology company leveraging deep understanding of immunobiolog...
Equillium is a biotechnology company leveraging...
Based in South San Francisco, we are a clinical-stage biotechnology company commit...
Based in South San Francisco, we are a clinical...
PhorMed is a clinical stage biopharmaceutical company located in Beverly Hills Cal...
PhorMed is a clinical stage biopharmaceutical c...
Join the National Investor Network and get the latest information with your interests in mind.